AstraZeneca's (LON:AZN) Lynparza (olaparib) will most likely experience payer pushback through prior authorization or step edits if it is FDA-approved for the maintenance setting in ovarian cancer, according to experts. Drug prescription limits could be another option to limit costs considering the longer and thus possibly more expensive treatment duration versus its current approval as a fourth-line drug in germline BRCA mutation (gBRCA) patients, they explained.
Lynparza is expected to remain in its current formulary tier 3-4 if approved for the maintenance setting, and patient copays will stay high, experts noted. The accompanying companion diagnostic will be looked upon favorably, but differential payer systems for the drug and diagnostic could create reimbursement delays, they added.
The Phase III SOLO-2 trial is in ovarian cancer patients with gBRCA mutations, and is expected to read out in late 2016 or early 2017, noted an investigator.